Response to 'communicating information about drug interactions'

British Journal of Clinical Pharmacology

Volumn 65, Issue 4, 2008, Pages 617-618

  Back, David J ^a   Gibbons, Sara E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; CYTOCHROME P450; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CLINICAL PRACTICE; DRUG CHOICE; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNET; LETTER; PERSONAL DIGITAL ASSISTANT; POLYPHARMACY; PRIORITY JOURNAL; TREATMENT PLANNING;

ANTI-RETROVIRAL AGENTS; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; ONLINE SYSTEMS;

EID: 40549105475     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03043.x     Document Type: Letter

References (6)

1. Aronson JK. Communicating information about drug interactions. Br J Clin Pharmacol 2007 63 : 637 9.
2. Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007 63 : 709 14.
3. HIV Drug Interactions. Available at http://www.hiv-druginteractions.org (last accessed 3 August 2007).
4. Sheehan NL, Kelly DV, Tseng AL, van Heeswijk RPG, Beique LC, Hughes CA. Evaluation of HIV drug interaction web sites. Ann Pharmacother 2003 37 : 1577 86.
5. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O, Lundgren J for the Eurosida Group. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005 21 : 743 52.
6. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 8 20 patients. BMJ 2004 329 : 15 9.